São Paulo, August 2014 Triple Negative Breast Cancer Do we have a “better” chemotherapy regimen? Carlos H. Barrios, M.D. | PUCRS School of Medicine| Porto Alegre, Brazil Potential Conflicts of Interest • No financial conflicts to declare • Consulting and research support – Roche, Astra Zeneca, Sanofi, Merck. Terminal Duct Lobular Unit (TDLU) Luminal Epithelial Cells Low molecular wt CK 7, 8, 18 and 19 Mucin, BCL2, Hormone Receptors Basal Cells (Myoepithelial cells) High molecular wt CK 5, 6, 14 and 17 SMA, Calponina, p63, P-caderin Perou C, et al. Nature 460:747-752, 2000 Smalley M. Ashworth A. Nat. Cancer Reviews 2003;3,832-844 Gene Expression of Breast Cancer Basal- like Group • Low HER2 cluster expression HER2 cluster Basal gene cluster Luminal (hormone receptor-related) cluster • Low ER (and related genes) expression Usually “triple negative” • High basal cluster – basal CK (5, 6, 14, 17) – EGFR, c-kit – others… • Very proliferative • Often p53 mutant Proliferation cluster • Evidence of genomic instability Basal-like Breast Cancer and Genomic Instability Array CGH in 89 LABC: % DNA copy number alterations Red=gain Green=loss Genome-wide aberrations Chromosome Bergamaschi et al, Genes Chromosomes Cancer, 2006. Triple-Negative vs. Basal-Like: Definitions ER- / PR- / HER2~15% of all breast carcinomas Poorly differentiated Express CK 5/6, 17, EGFR (+) 1. 2. 3. 4. 5. • Triple negative but not basal • Definition by IHC • Includes other histologies (medullar, adenoid cystic) • 10-30% can also include “claudinlow,” a subtype notable for high expression of stem cell markers • 90% of TNBC do not have BRCA mutations ~75% of TNBC have Basal gene expression Triple Negative Pal & Mortimer. Maturitas 2009; Gluz et al. Ann Oncol 2009; Anders & Carey. Oncology 2008. Young et al. BMC Cancer 2009 Schneider, B. P. et al. Clin Cancer Res 2008;14:8010-8018 Basal BRCA 1-2 • BRCA1-2 mutated tumors •~5% of Breast Cancer • 50% BRCA-1 carriers are basal-like • Basal but not triple negative • Definition by gene expression • Includes most BRCA1 mutated tumors • 15-40% are ER+, PR+ or HER2+ Deconstructing the Molecular Portraits of Breast Cancer: TNBC gene expression profiles Prat A, Perou C. Molecular Oncology, Nov 24, 2010 (PMID: 21147047) Genomic Analyses of Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity 55% of Basal-like breast tumors were found more similar to SQCLC than to non-basal breast cancers. Luminal A (76%), Luminal B (72%) and HER2-enriched (17%) breast tumors. Prat A, et al. Sci Rep 2013 Lehmann B, et al. JCI, 121:2750, 2011 Number of samples with aberrations Clinically targetable pathways in TNBC 40 TSC1 AKT3 AKT2 AKT1 RAPTOR RICTOR 30 ~90% of all patients had an aberration in at least one of these pathways RB1 AURKA CDNK2A 20 CCNE1 PTEN CCND3 PIK3R1 BRCA2 10 PI3K/mTOR PI3K/mTOR inhibitors NF1 BRCA1 PIK3CA 0 ATM DNA Repair DNA-repair targeting agents MET CCND2 CRAF BRAF KRAS Ras/MAPK RAF/MEK inhibitors FGFR4 CCND1 CDK6 IGF1R CDK4 Cell Cycle Cell cycle/mitotic spindle inhibitors FGFR1 KIT FGFR2 EGFR GFRs Targeted RTK inhibitors Arteaga C, et al. Vanderbilt Take Home • TN Breast cancers represent an heterogeneous group of diseases • Highly complex and genetically unstable • Should consider the challenge of a molecular vs. a histological classification Basal-like BC Responds to Conventional Chemotherapy Pathologic Complete Response: T-FAC (N=82)* AC-T (n=107)* Luminal A/B 7% 7% Normal-like 0 NA HER2+/ER- 45% 36% Basal-like/triple negative 45% 26% • Basal-like / triple negative breast cancer responds to primary chemotherapy. Explanation of higher response but worse outcome? Rouzier, et al. Clin Cancer Res, 2005 Carey LA, et al. Clin Cancer Res 2007 TNBC: Responsiveness to Neoadjuvant Conventional Chemotherapy TNBC is responsive to conventional NAC with good outcome similar to other subtypes < pCR = poorer outcome 1.0 Probability of Being Alive • • 98% 94% P = .24 0.9 88% 0.8 P = .0001 0.7 68% 0.6 0.5 pCR/non-TNBC pCR/TNBC RD/non-TNBC RD/TNBC 0.4 1 2 3 4 5 Yrs After Surgery 6 7 Liedtke C, et al. J Clin Oncol. 2008;26:1275-1281. TIL are prognostic in TNBC treated with adjuvant chemotherapy (BIG 02-98) RCT 2009 patients (256 TNBC) A-CMF vs. AC-CMF Highest TIL in HER2 and TNBC Prognostic correlation in TNBC (not in the other subtypes) Continuous: better with each 10% Binary: LPBC (>50% better) Loi S et al. JCO 2013 Take Home • TN Breast cancers respond to conventional chemotherapy • Strong prognostic value of Response to Neoadjuvant Chemotherapy • Strong prognostic value of TIL Bevacizumab for TNBC Trial / Arm Median PFS (m) in TNBC Subset E2100 Paclitaxel (n=110) 5.3 Paclitaxel + bevacizumab (n=122) 10.6 AVADO Docetaxel + placebo (n=52) 5.4 Docetaxel + bevacizumab 15 mg/kg (n=58) 8.2 RIBBON-1 Taxane/anthracycline + placebo (n=46) 6.2 Taxane/anthracycline + bevacizumab (n=96) 6.5 Capecitabine + placebo (n=50) 4.2 Capecitabine + bevacizumab (n=87) 6.1 ATHENA Taxane-based regimen + bevacizumab (n=577) *Median PFS vs non-TNBC subgroup. No Survival data available in the TNBC subset 7.2* EGFR Inhibition for TNBC Efficacy data from phase II trials TBCRC 001 (n=102) O’Shaugnessy et al (n=78) Cetuximab Carboplatin + Cetuximab Irinotecan + Carboplatin Irinotecan + Carboplatin + Cetuximab ORR,% 6 18 49 30 Clinical benefit, % 10 27 NR NR 5.1 4.7 PFS, mo 2 • TNBC is strongly associated with EGFR expression • EGFR inhibitors combined with platinum • Current data are conflicting NR=not reported; PFS=progression-free survival; RR=response rate; TBCRC=Translational Breast Cancer Research Consortium Carey et al. ASCO 2008; abstr 1009; O’Shaughnessy et al. SABCS 2007; abstr 308. I-Spy 2 Trial Neoadjuvant Veliparib/Carboplatin followed by wPac/AC Rugo H, et al. SABCS 2013 CALGB/Alliance 40603 pCR in Breast and Axilla TNBC Patients ER 1-10% (6%) Age <60 T2-T3 LN+ Grade III 83% 86% 55% 86% Sikov W, et al. SABCS 2013 The Role of Carboplatin in TNBC (Neo) Trial N CALGB 40603 443 Standard Chemotherapy Chemo + Carboplatin P-value 41% 54% 0.003 I-SPY 2 NA 26% 52% 90% prob. for superiority GeparSixto (TNBC pts) 315 38% 59% <0.05 Sikov W, et al. SABCS 2013. Rugo H, et al. SABCS 2013. Von Minckwitz G, et al, The Lancet Oncology 15:747, 2014. Platinum-sensitivity of BRCA1mut TNBCs Trial Byrski Silver Ryan • • Characteristics Regimen n° pRC BRCA1+mut carriers Not-platinum-based 90 14 (16%) BRCA1+mut carriers CDDP 75mg/m2 x4 12 10 (83%) Sporadic TNBCs (not BRCA1+mut carriers) CDDP 75mg/m2 x4 26 4 (15%) BRCA1mut carriers CDDP 75mg/m2 x4 2 2 (100%) Sporadic TNBCs (not BRCA1+mut carriers) CDDP 75mg/m2 x4 + bevacizumab 15 mg/kg q3wk x3 51 8 (16%) Neo-adjuvant setting: – Retrospective trials suggest platinum-based regimens activity; – Data from prospective trials on TNBCs are controversial; Metastatic TNBCs: – control arm in BALI-1 study with DDP alone – 10% RR Byrski, JCO 2009; Silver JCO 2009: Baselga ESMO 2010; Isakoff SABCS 2010 Phase II Trial of Olaparib in BRCA Deficient MBC •Multicenter POC phase II, single-arm sequential cohort •Confirmed BRCA1 or BRCA2 mutation •Advanced refractory breast cancer (stage IIIB/IIIC/IV after failure of ≥1 prior CT for advanced disease) ITT cohort Overall Response Rate, n (%) Complete Response, n (%) Partial Response, n (%) Olaparib 400 mg bid (n=27) Olaparib 100 mg bid (n=27) 11 (41) 6 (22) 1 (4) 0 10 (37) 6 (22) MTD, maximum tolerated dose (determined during Phase I evaluation) Audeh et al. ASCO 2009. Abstract #5500 TNBC recent perspectives Looking for a target... • • • • • • • • • Other Chemotherapy? Androgen Receptor PI3K pathway alterations EGFR inhibitors Anti-angiogenics Src inhibitors C-Kit alteration Clinical Trail Likely will need combos TNBC: Conclusions • TNBC is a recognized distinct subtype of BC – ER, PR, HER2-negative by IHC • Surrogate of basal-like BC – More aggressive biology (morphology, clinical, molecular) • TNBC responds to a variety of CT agents although no specific standard regimen or agent can be singled out • TNBC has no identified specific therapeutic target • Represents an heterogeneous group of tumors probably with different response patterns to different treatments – Introduction of novel agents (PARPi, others) ? – Biomarkers: RAD-51, Neuropilin ?